Wednesday, April 23, 2008

Stem cell cure hope for MS patients

Stem cell cure hope for MS patients
The Press Association -
Stem-cell treatment could be used to help reverse the effects of multiple sclerosis within 15 years, a leading expert on the disease has said. ...
See all stories on this topic

Scots health pioneers ‘will reverse MS damage in 15 years’
The Herald - Glasgow,Scotland,UK
The effects of multiple sclerosis could be reversed within 15 years using stem-cell treatment, the head of a groundbreaking Scottish research centre said ...
See all stories on this topic

Scots health pioneers ‘will reverse MS damage in 15 years’
The Herald Tue, 22 Apr 2008 4:16 PM PDT
The effects of multiple sclerosis could be reversed within 15 years using stem-cell treatment, the head of a groundbreaking Scottish research centre said yesterday.
Pregnancy hormone may protect MS patients
Belleville News-Democrat Tue, 22 Apr 2008 4:39 AM PDT
When women with remitting-relapsing multiple sclerosis (MS) become pregnant, they often can look forward to a double blessing
New Campaign Launched During MS Week
Medical News Today Tue, 22 Apr 2008 3:13 AM PDT
The MS Society has launched this week's MS Week 2008 with a series of new adverts featuring images and words of people with multiple sclerosis (MS).The four new adverts encourage people living with the condition to explore the help that is out there, whether through the MS Society's branch network, self management courses, through online support forums, or via personalised care.

Active Biotech upgraded to "buy"
newratings.com - Westerburg,Germany
FTY720 is unlikely to get an approval as a first-line treatment, the analysts say. Following this data from Novartis, the peak sales estimate for Laquinimod ...
See all stories on this topic


Daily Mirror - Colombo,Western,Sri Lanka
Mendis feels that there are other diseases that are neglected in our country which include Cerebral Palsy, Multiple Sclerosis and Alzheimer’s. ...
See all stories on this topic

ALSO NOTED: Stem cells can treat irregular heartbeats; Gene ...
FierceBioResearcher - Washington,DC,USA
... of new mouse models for autoimmune diseases such as multiple sclerosis and type 1 diabetes, in which the body attacks certain types of its own cells. ...
See all stories on this topic

Marathon efforts are big boost for charity
Petersfield Today - Petersfield,England,UK
Keith Budge, headteacher of Bedales School, was also running for Higgy’s Heroes, a multiple sclerosis charity charity run by Alastair Hignell, an ex-England ...
See all stories on this topic


Genentech And Biogen Idec Announce Top-Line Results From A Phase II/III Clinical Trial Of Rituxan In Primary-Progressive Multiple Sclerosis
Genentech, Inc. (NYSE: DNA) and Biogen Idec, Inc. (Nasdaq: BIIB) announced that a Phase II/III study of Rituxan® (rituximab) for primary-progressive multiple sclerosis (PPMS) did not meet its primary endpoint as measured by the time to confirmed disease progression during the 96-week treatment period.
Potential MS Therapy Advanced By Minnesota Partnership
A production laboratory founded by the Minnesota Partnership has transferred its first potential therapy - a medication for multiple sclerosis - to a processing plant in Minnesota. This step will complete purification of material to fully enable translation from preclinical to clinical development.
Idera Pharmaceuticals Presents Data From Study Of Toll-Like Receptor Antagonist In Preclinical Model Of Multiple Sclerosis
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), announced the presentation of data from studies evaluating a Toll-Like Receptor (TLR) antagonist in a preclinical model of multiple sclerosis (MS).
Genentech And Biogen Idec Announce Top-Line Results From A Phase II/III Clinical Trial Of Rituxan In Primary-Progressive Multiple Sclerosis
Genentech, Inc. (NYSE: DNA) and Biogen Idec, Inc. (Nasdaq: BIIB) announced that a Phase II/III study of Rituxan® (rituximab) for primary-progressive multiple sclerosis (PPMS) did not meet its primary endpoint as measured by the time to confirmed disease progression during the 96-week treatment period.
Vaccines 'Golden Era' Is Under Threat
The development of vaccines is on the verge of a 'golden era' - but it may be threatened if the drive to cut costs by governments, including the UK, is carried out regardless of long-term health consequences, a leading academic warned.
Mouse Studies Show Tumors Suppress Cells Responsible For Regulating The Immune System
New research has shown that the function of a type of cell that helps modulate immune responses is impaired inside tumors in mice. Researchers also identified several factors that may contribute to an accumulation of these cells, called T regulatory cells (Tregs), within and around the tumor, which may be how they respond to their loss of functionality.

0 Comments:

Post a Comment

Links to this post:

Create a Link

<< Home